On April 7, 2025, New Mexico Governor Michelle Lujan Grisham signed into law SB-219, the Medical Psilocybin Act (the Act), making New Mexico the third state in the country to create a legal pathway for patients to access...more
4/10/2025
/ Controlled Substances ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Healthcare ,
Medical Research ,
Mental Health ,
New Legislation ,
Patient Access ,
Physicians ,
Public Health ,
State and Local Government
On July 10, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule Proposed Rule (Proposed Rule) for the calendar year 2025. The Proposed Rule would implement certain provisions of the...more
7/30/2024
/ Centers for Medicare & Medicaid Services (CMS) ,
Drug Treatment ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Medicaid ,
Medicare ,
Opioid ,
Physician Fee Schedule ,
Popular ,
Proposed Rules ,
SAMHSA ,
Substance Abuse ,
Telemedicine
The U.S. Food and Drug Administration (FDA) recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of cannabidiol...more
On June 26, 2023, the U.S. Food and Drug Administration (FDA) issued its first draft guidance entitled Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry (Guidance), which highlights...more
Congress recently introduced a bill that could expand access to therapeutic psychedelics that are designated as Breakthrough Therapies. These products are potentially useful in treating addiction, depression, post-traumatic...more